Table 3.

Clinical Features of Bone Marrow-Augmented Intestinal Recipients and Control Patients

	BM-augmented group (n = 20)	Control group (n = 22)
Children/adult	13/7	16/6
Male/female	9/11	16/6
Allograft
Intestine	8 (40%)	7 (32%)
Composite	12 (60%)	15 (68%)
Duration of TPN (mo)	59 ± 53	49 ± 49
Total bilirubin (mg/dL)	17 ± 15	21 ± 16
No. of abdominal operations	5 ± 4	4 ± 3
Operative time (h)	14 ± 6	14 ± 4
Cold ischemia time (h)	9.7 ± 2.8	9.2 ± 3.0
HLA (-A, -B, -DR) mismatch	4.4 ± 1.1	4.4 ± 1.1
Positive cytotoxic cross-match	2 (10%)	6 (27%)
Followup (mo)	13 ± 12	13 ± 11

BM, bone marrow; TPN, total parenteral nutrition.